Caribou Biosciences, Inc.
CRBU
$0.7331
-$0.046-5.90%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -71.01% | -66.85% | 132.34% | 127.41% | 148.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -71.01% | -66.85% | 132.34% | 127.41% | 148.91% |
| Cost of Revenue | 15.06% | 22.37% | 31.85% | 27.80% | 36.29% |
| Gross Profit | -53.30% | -65.31% | -14.73% | -9.36% | -13.48% |
| SG&A Expenses | 10.65% | 12.12% | 21.78% | 18.37% | 1.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.93% | 19.72% | 29.07% | 25.12% | 25.19% |
| Operating Income | -39.17% | -47.15% | -16.91% | -12.24% | -9.08% |
| Income Before Tax | -46.37% | -56.56% | -10.90% | -6.24% | -2.54% |
| Income Tax Expenses | -104.66% | 175.71% | 175.71% | 175.71% | 175.71% |
| Earnings from Continuing Operations | -46.08% | -56.65% | -11.01% | -6.35% | -2.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.08% | -56.65% | -11.01% | -6.35% | -2.66% |
| EBIT | -39.17% | -47.15% | -16.91% | -12.24% | -9.08% |
| EBITDA | -40.04% | -48.44% | -15.77% | -10.93% | -7.40% |
| EPS Basic | -14.03% | -10.12% | 23.66% | 18.33% | 11.39% |
| Normalized Basic EPS | -10.32% | -6.73% | 23.78% | 18.34% | 11.34% |
| EPS Diluted | -14.03% | -10.12% | 23.66% | 18.33% | 11.39% |
| Normalized Diluted EPS | -10.32% | -6.73% | 23.78% | 18.34% | 11.34% |
| Average Basic Shares Outstanding | 22.54% | 34.09% | 43.91% | 32.44% | 21.23% |
| Average Diluted Shares Outstanding | 22.54% | 34.09% | 43.91% | 32.44% | 21.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |